GSK/CNS deal complete
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has completed its $566 million acquisition of Breathe Right and FiberChoice maker CNS, the firm announces Dec. 19. "The opportunity for growth through geographic expansion make[s] this an exciting prospect," GSK Consumer Healthcare President John Clarke said. FiberChoice is sold only in the U.S., but Breathe Right is sold in 26 countries including Hong Kong, Mexico, South Africa and Portugal, according to GSK. The acquisition should help CNS protect the intellectual property rights and market share of its Breathe Right brand, the firm said in a filing with the Securities & Exchange Commission (1"The Tan Sheet" Nov. 6, 2006, p. 3)...